346 related articles for article (PubMed ID: 30368668)
1. Delineation of LZTR1 mutation-positive patients with Noonan syndrome and identification of LZTR1 binding to RAF1-PPP1CB complexes.
Umeki I; Niihori T; Abe T; Kanno SI; Okamoto N; Mizuno S; Kurosawa K; Nagasaki K; Yoshida M; Ohashi H; Inoue SI; Matsubara Y; Fujiwara I; Kure S; Aoki Y
Hum Genet; 2019 Jan; 138(1):21-35. PubMed ID: 30368668
[TBL] [Abstract][Full Text] [Related]
2. Expanding the clinical phenotype of RASopathies in 38 Turkish patients, including the rare LZTR1, RAF1, RIT1 variants, and large deletion in NF1.
Uludağ Alkaya D; Lissewski C; Yeşil G; Zenker M; Tüysüz B
Am J Med Genet A; 2021 Dec; 185(12):3623-3633. PubMed ID: 34184824
[TBL] [Abstract][Full Text] [Related]
3. Providing more evidence on LZTR1 variants in Noonan syndrome patients.
Chinton J; Huckstadt V; Mucciolo M; Lepri F; Novelli A; Gravina LP; Obregon MG
Am J Med Genet A; 2020 Feb; 182(2):409-414. PubMed ID: 31825158
[TBL] [Abstract][Full Text] [Related]
4. Delineation of dominant and recessive forms of LZTR1-associated Noonan syndrome.
Pagnamenta AT; Kaisaki PJ; Bennett F; Burkitt-Wright E; Martin HC; Ferla MP; Taylor JM; Gompertz L; Lahiri N; Tatton-Brown K; Newbury-Ecob R; Henderson A; Joss S; Weber A; Carmichael J; Turnpenny PD; McKee S; Forzano F; Ashraf T; Bradbury K; Shears D; Kini U; de Burca A; ; Blair E; Taylor JC; Stewart H
Clin Genet; 2019 Jun; 95(6):693-703. PubMed ID: 30859559
[TBL] [Abstract][Full Text] [Related]
5. Rare variants in SOS2 and LZTR1 are associated with Noonan syndrome.
Yamamoto GL; Aguena M; Gos M; Hung C; Pilch J; Fahiminiya S; Abramowicz A; Cristian I; Buscarilli M; Naslavsky MS; Malaquias AC; Zatz M; Bodamer O; Majewski J; Jorge AA; Pereira AC; Kim CA; Passos-Bueno MR; Bertola DR
J Med Genet; 2015 Jun; 52(6):413-21. PubMed ID: 25795793
[TBL] [Abstract][Full Text] [Related]
6. Activating MRAS mutations cause Noonan syndrome associated with hypertrophic cardiomyopathy.
Motta M; Sagi-Dain L; Krumbach OHF; Hahn A; Peleg A; German A; Lissewski C; Coppola S; Pantaleoni F; Kocherscheid L; Altmüller F; Schanze D; Logeswaran T; Chahrokh-Zadeh S; Munzig A; Nakhaei-Rad S; Cavé H; Ahmadian MR; Tartaglia M; Zenker M
Hum Mol Genet; 2020 Jul; 29(11):1772-1783. PubMed ID: 31108500
[TBL] [Abstract][Full Text] [Related]
7. Targeted/exome sequencing identified mutations in ten Chinese patients diagnosed with Noonan syndrome and related disorders.
Xu S; Fan Y; Sun Y; Wang L; Gu X; Yu Y
BMC Med Genomics; 2017 Oct; 10(1):62. PubMed ID: 29084544
[TBL] [Abstract][Full Text] [Related]
8. A novel rasopathy caused by recurrent de novo missense mutations in PPP1CB closely resembles Noonan syndrome with loose anagen hair.
Gripp KW; Aldinger KA; Bennett JT; Baker L; Tusi J; Powell-Hamilton N; Stabley D; Sol-Church K; Timms AE; Dobyns WB
Am J Med Genet A; 2016 Sep; 170(9):2237-47. PubMed ID: 27264673
[TBL] [Abstract][Full Text] [Related]
9. LZTR1: Genotype Expansion in Noonan Syndrome.
Güemes M; Martín-Rivada Á; Ortiz-Cabrera NV; Martos-Moreno GÁ; Pozo-Román J; Argente J
Horm Res Paediatr; 2019; 92(4):269-275. PubMed ID: 31533111
[TBL] [Abstract][Full Text] [Related]
10. The novel RAF1 mutation p.(Gly361Ala) located outside the kinase domain of the CR3 region in two patients with Noonan syndrome, including one with a rare brain tumor.
Harms FL; Alawi M; Amor DJ; Tan TY; Cuturilo G; Lissewski C; Brinkmann J; Schanze D; Kutsche K; Zenker M
Am J Med Genet A; 2018 Feb; 176(2):470-476. PubMed ID: 29271604
[TBL] [Abstract][Full Text] [Related]
11. Dominant Noonan syndrome-causing LZTR1 mutations specifically affect the Kelch domain substrate-recognition surface and enhance RAS-MAPK signaling.
Motta M; Fidan M; Bellacchio E; Pantaleoni F; Schneider-Heieck K; Coppola S; Borck G; Salviati L; Zenker M; Cirstea IC; Tartaglia M
Hum Mol Genet; 2019 Mar; 28(6):1007-1022. PubMed ID: 30481304
[TBL] [Abstract][Full Text] [Related]
12. Noonan syndrome with loose anagen hair with variants in the PPP1CB gene: First familial case reported.
Huckstadt V; Chinton J; Gomez A; Obregon MG; Gravina LP
Am J Med Genet A; 2021 Apr; 185(4):1256-1260. PubMed ID: 33491856
[TBL] [Abstract][Full Text] [Related]
13. Clinical and molecular characterization of children with Noonan syndrome and other RASopathies in Argentina.
Chinton J; Huckstadt V; Moresco A; Gravina LP; Obregon MG
Arch Argent Pediatr; 2019 Oct; 117(5):330-337. PubMed ID: 31560489
[TBL] [Abstract][Full Text] [Related]
14. A severe clinical phenotype of Noonan syndrome with neonatal hypertrophic cardiomyopathy in the second case worldwide with RAF1 S259Y neomutation.
Jaouadi H; Chehida AB; Kraoua L; Etchevers HC; Argiro L; Kasdallah N; Blibech S; Delague V; Lévy N; Tebib N; Mrad R; Abdelhak S; Benkhalifa R; Zaffran S
Genet Res (Camb); 2019 Apr; 101():e6. PubMed ID: 31030682
[TBL] [Abstract][Full Text] [Related]
15. A Chinese family with Noonan syndrome caused by a heterozygous variant in LZTR1: a case report and literature review.
Zhao X; Li Z; Wang L; Lan Z; Lin F; Zhang W; Su Z
BMC Endocr Disord; 2021 Jan; 21(1):2. PubMed ID: 33407364
[TBL] [Abstract][Full Text] [Related]
16. Inducible Pluripotent Stem Cell-Derived Cardiomyocytes Reveal Aberrant Extracellular Regulated Kinase 5 and Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Concomitantly Promote Hypertrophic Cardiomyopathy in RAF1-Associated Noonan Syndrome.
Jaffré F; Miller CL; Schänzer A; Evans T; Roberts AE; Hahn A; Kontaridis MI
Circulation; 2019 Jul; 140(3):207-224. PubMed ID: 31163979
[TBL] [Abstract][Full Text] [Related]
17. Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation.
Kobayashi T; Aoki Y; Niihori T; Cavé H; Verloes A; Okamoto N; Kawame H; Fujiwara I; Takada F; Ohata T; Sakazume S; Ando T; Nakagawa N; Lapunzina P; Meneses AG; Gillessen-Kaesbach G; Wieczorek D; Kurosawa K; Mizuno S; Ohashi H; David A; Philip N; Guliyeva A; Narumi Y; Kure S; Tsuchiya S; Matsubara Y
Hum Mutat; 2010 Mar; 31(3):284-94. PubMed ID: 20052757
[TBL] [Abstract][Full Text] [Related]
18. Autosomal recessive Noonan syndrome associated with biallelic LZTR1 variants.
Johnston JJ; van der Smagt JJ; Rosenfeld JA; Pagnamenta AT; Alswaid A; Baker EH; Blair E; Borck G; Brinkmann J; Craigen W; Dung VC; Emrick L; Everman DB; van Gassen KL; Gulsuner S; Harr MH; Jain M; Kuechler A; Leppig KA; McDonald-McGinn DM; Can NTB; Peleg A; Roeder ER; Rogers RC; Sagi-Dain L; Sapp JC; Schäffer AA; Schanze D; Stewart H; Taylor JC; Verbeek NE; Walkiewicz MA; Zackai EH; Zweier C; ; Zenker M; Lee B; Biesecker LG
Genet Med; 2018 Oct; 20(10):1175-1185. PubMed ID: 29469822
[TBL] [Abstract][Full Text] [Related]
19. High frequency of hotspot mutation in PTPN11 gene among Moroccan patients with Noonan syndrome.
Ouboukss F; Adadi N; Amasdl S; Smaili W; Laarabi FZ; Lyahyai J; Sefiani A; Ratbi I
J Appl Genet; 2024 May; 65(2):303-308. PubMed ID: 37987971
[TBL] [Abstract][Full Text] [Related]
20. MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation.
Wu X; Simpson J; Hong JH; Kim KH; Thavarajah NK; Backx PH; Neel BG; Araki T
J Clin Invest; 2011 Mar; 121(3):1009-25. PubMed ID: 21339642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
